Typewriter Therapeutics: Funding Rounds, Investors & CEO

About Typewriter Therapeutics

Typewriter Therapeutics develops genetic medicines for cancer, autoimmune diseases and severe genetic diseases. Its therapy packs two RNAs into a lipid nanoparticle and inserts a complete working gene at one natural site in the genome. It needs no virus, and the gene stays in place as cells divide.

Its first two programs are in vivo CAR-T and gene insertion in the liver for rare diseases. In vivo CAR-T engineers a patient's T cells inside the body instead of in a lab. Typewriter started in February 2022, building on research into R2 retrotransposons by Haruhiko Fujiwara of the University of Tokyo and Tom Eickbush of the University of Rochester. It has research sites in Cambridge, Massachusetts, and Tokyo. CEO Matthew Stanton was previously chief scientific officer of Generation Bio, and Ken Horne of AN Venture Partners chairs the board.

Funding Rounds (SEC Form D)

First sale	Filed with SEC	Amount sold	Investors	Avg. check	Terms	Filing
Jan 8, 2026	Sep 21, 2026	$56,299,999fully sold	6	$9.3M	EquityRule 506(b)	Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Rounds announced by Typewriter Therapeutics

What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.

Announced	Round	Amount	Investors	Source
Sep 2, 2026	Series A	$56M	AN Venture Partners and RA Capital Management (co-leads), ANRI, Gemseki, SBI US Gateway Fund	typewritertx.com ↗ Press release ↗ AN Venture Partners ↗

Why Investors Backed Typewriter Therapeutics

Investors backed Typewriter Therapeutics for a new way to add whole genes to a patient’s DNA. Its medicine uses only RNA, needs no virus and does not cut both DNA strands. The method grew out of decades of R2 research by co-founders in Tokyo and Rochester. Its first target is in vivo CAR-T, a field where AbbVie, AstraZeneca and Eli Lilly have paid billions for startups since 2025.

The problem it targets

CAR-T therapies already treat some cancers, but labs make each dose outside the body. They collect a patient’s T cells, engineer them and grow them before infusing them back. Typewriter calls this process slow, costly and complex. H.C. Wainwright analyst Mitchell Kapoor made the same point to BioSpace: “What it doesn’t do is scale.” Many genetic diseases also need a whole new gene, not a small edit. Viral carriers limit the size of the gene and insert it semi-randomly. Immune reactions to the virus can also rule out a second dose.

What the product does

Typewriter packs two RNAs into one lipid nanoparticle. One is an mRNA that makes the R2 protein. The other carries the therapeutic gene, flanked by sequences that recruit R2. Inside the cell, the two form a complex that inserts the gene at one specific site. Afterward, the R2 machinery breaks down, and only the new gene stays. Because the gene sits in the cell’s DNA, dividing cells keep it. The company plans two uses: making CAR-T cells inside the body, and adding genes to the liver for rare diseases.

Progress so far

Typewriter is still preclinical. It has proof of concept in humanized mouse models. It plans its first studies in non-human primates for late 2026. CEO Matthew Stanton said the Series A will help it “establish our first in vivo CAR T development candidate.”

Who backs it

AN Venture Partners and RA Capital Management co-led the $56 million Series A, and ANRI, Gemseki and SBI US Gateway Fund joined. AN builds U.S. companies around Japanese science, and it closed its first fund at $200 million in July 2025. Its managing partner, Ken Horne, chairs Typewriter’s board. RA managing director Laura Tadvalkar is a director, and Stanton came from Raven, RA Capital’s incubator. RA has backed in vivo CAR-T before: it joined the 2021 seed round of Capstan, which AbbVie agreed to buy in 2025. Japan’s medical research agency, AMED, also picked Typewriter for a startup support program, AN said in July 2025.

How the market is moving

Big drugmakers have been buying in vivo CAR-T developers. AstraZeneca bought EsoBiotec in March 2025 for up to $1 billion, including milestones. AbbVie agreed in June 2025 to pay up to $2.1 billion for Capstan. Eli Lilly paid $2.4 billion for Orna Therapeutics in February 2026. In April, it agreed to buy Kelonia Therapeutics for up to $7 billion, according to BioSpace. Gene writing is drawing money too. In October 2025, ARPA-H granted Tessera Therapeutics up to $41.3 million for in vivo CAR-T work. Two months later, Regeneron agreed to pay Tessera $150 million in cash and equity to co-develop a therapy.

We wrote this summary from public statements by Typewriter Therapeutics and its investors. It is not investment advice.